Acute intermittent porphyria (AIP) treatment ranges from emergency infusions of intravenous hemin during attacks to newer preventive therapies that can drastically cut the number of crises a person experiences. The landscape has shifted in the past several years with the approval of givosiran, an RNA-based drug that targets the disorder’s root biochemistry, but hemin and supportive care remain the backbone for most patients. How treatment is chosen depends on attack frequency, severity, and individual triggers, and the calculus is different for someone who has one episode a year compared to someone dealing with monthly hospitalizations.
What Happens During an Attack and Why It Matters for Treatment
AIP is caused by mutations in the gene encoding the third enzyme in the body’s heme-making pathway. Most people who carry the mutation never get sick; clinical penetrance is low. But in those who do have attacks, certain triggers cause the liver to ramp up production of heme precursors that accumulate to toxic levels.1PubMed Central. Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators Those precursors, particularly one called ALA, damage nerves throughout the body, producing the hallmark symptoms: severe abdominal pain, nausea, vomiting, confusion, rapid heart rate, and sometimes dangerous drops in sodium levels or muscle weakness that can progress to paralysis.
Understanding this chain of events matters because almost every treatment for AIP works by interrupting it at some point. Hemin shuts down the overactive enzyme at the top of the chain. Givosiran silences the gene that codes for that enzyme before it can ramp up. Glucose loading provides a weaker version of the same braking signal. Even trigger avoidance works by preventing the chain from starting in the first place.
Treating an Acute Attack
When someone shows up in an emergency department mid-crisis, speed matters. Expert recommendations call for confirming the diagnosis quickly with a urine test showing elevated porphobilinogen, then starting intravenous hemin as soon as possible.2PubMed. Recommendations for the diagnosis and treatment of the acute porphyrias Hemin works by expanding the pool of regulatory heme inside liver cells, which activates a feedback loop that tells the liver to stop overproducing the toxic precursors.3PubMed Central. Acute Hepatic Porphyria The effect is relatively fast: precursor levels begin dropping within hours, and symptoms often improve within a day or two of starting treatment.
Before hemin became available, the main option was intravenous glucose, which provides a milder version of the same suppressive signal. High-dose glucose infusions are still used when hemin is not immediately available, or for mild attacks. But hemin is substantially more effective, and delaying it in favor of glucose in a serious attack can allow nerve damage to progress.
Supportive care during an attack covers a list of problems that are individually manageable but collectively dangerous. Pain typically requires opioids, since many common painkillers are unsafe in porphyria. Nausea may need anti-emetics. Seizures require careful drug selection because several standard anti-seizure medications can worsen porphyria. Hyponatremia, which is common during attacks, should be corrected slowly to avoid making neurological damage worse.4PubMed Central. Management of hyponatremia associated with acute porphyria-proposal for the use of tolvaptan In the most severe cases, motor nerve damage can cause breathing failure requiring a ventilator and intensive care.5PubMed Central. Intensive care management of patients with acute intermittent porphyria: Clinical report of four cases and review of literature
Drug Safety and Trigger Avoidance
One of the trickiest parts of living with AIP is that a surprisingly long list of common medications can trigger attacks. The core problem is that many drugs get processed by liver enzymes called cytochrome P450s, and revving up those enzymes depletes the liver’s heme supply, which in turn drives the overproduction of toxic precursors.6Pharmacology & Therapeutics. Drugs in porphyria: From observation to a modern algorithm-based system for the prediction of porphyrogenicity Barbiturates, sulfonamides, certain anti-seizure drugs, and some hormonal preparations are well-known offenders, but the full list runs into the hundreds.
Online databases maintained by porphyria centers (the most widely referenced ones originate from European and South African groups) classify drugs into safe, unsafe, and uncertain categories. For anyone with AIP, checking every new prescription or over-the-counter medication against one of these databases is essential. The same goes for herbal supplements, many of which have never been formally evaluated for porphyrogenicity. Beyond medications, fasting, heavy alcohol use, stress, and hormonal fluctuations are common triggers. Keeping caloric intake steady and avoiding crash diets is a surprisingly practical piece of the treatment puzzle.
Givosiran and the Shift Toward Prevention
For decades, AIP treatment was almost entirely reactive: wait for an attack, then treat it. Givosiran, approved for adults and adolescents aged 12 and older, changed that equation. It is an RNA interference drug, given as a monthly injection under the skin, that silences the gene for the enzyme sitting at the very top of the heme production pathway. By keeping that enzyme from ramping up, givosiran prevents the surge of toxic precursors that causes attacks.7PubMed. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria
The clinical data behind it is striking. In a phase 1 trial, patients receiving monthly givosiran injections saw their precursor levels drop to near normal, with a roughly 79% lower annualized attack rate compared to placebo.8PubMed. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria The larger phase 3 trial confirmed that givosiran reduces attack rates and lowers the accumulation of the precursors that drive both acute crises and chronic symptoms.9PubMed. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
There are trade-offs. While generally well tolerated, givosiran can increase the risk of liver and kidney problems, which means patients on the drug need regular blood work to watch for those complications.10PubMed. Givosiran: A Review in Acute Hepatic Porphyria This is particularly worth watching because AIP itself already predisposes people to kidney disease, so stacking a drug-related kidney risk on top of a disease-related one is something clinicians monitor closely.
Prophylactic Hemin for Frequent Attackers
Before givosiran, the main option for people with very frequent attacks was regularly scheduled hemin infusions, typically once a week, given through a central venous catheter even when the person was not in crisis. A case series of patients who had been requiring nearly monthly hospitalizations illustrated the potential: one patient went from 11 inpatient admissions in 12 months to zero after starting weekly prophylactic hemin, with only a single emergency visit (for nausea, managed without admission). A second patient dropped from 13 admissions over 12 months to just three emergency visits over 11 months of follow-up.11PubMed Central. Benefits of prophylactic heme therapy in severe acute intermittent porphyria
Prophylactic hemin still has a role, especially where givosiran is unavailable or contraindicated. But it requires a permanent central venous line, which carries infection and clotting risks, and repeated hemin infusions can cause iron overload over time. From a cost standpoint, hemin-based treatment is substantially cheaper. One economic analysis found that the average annual total cost of care with hemin was about 78% lower than with givosiran, a difference of roughly $482,000 per year per patient across all AIP patients studied.12Taylor & Francis Online (Journal of Medical Economics). Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP) Even in patients already on hemin prophylaxis, the cost difference was still large. This economic reality shapes treatment decisions in many healthcare systems worldwide.
Hormonal Management for Menstrual-Related Attacks
A substantial subset of women with AIP experience attacks that follow the menstrual cycle, typically flaring in the days before a period. The hormonal shifts of the luteal phase trigger the same enzyme overactivity that other porphyrogenic factors do. For these women, suppressing ovulation can be transformative.
The most studied approach uses GnRH agonists, drugs that shut down the hormonal cycling by suppressing the signals from the brain that drive ovulation. In one evaluation of this approach, 11 women reported less intense or less frequent attacks, and in four of them attacks nearly disappeared.13PubMed. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria Earlier reports documented sustained benefits for up to 26 months with only minor side effects, and concluded that GnRH agonists are a safe alternative to exogenous steroids, which can actually induce attacks.14JAMA Internal Medicine. A Gonadotropin Releasing Hormone Analogue Prevents Cyclical Attacks of Porphyria Other groups have confirmed these findings, describing ovulation suppression as valuable for young women with cycle-related crises.15QJM: An International Journal of Medicine. LHRH Analogue Treatment for the Prevention of Premenstrual Attacks of Acute Porphyria
The downside is that GnRH agonists create a temporary menopausal state, with hot flashes, bone density loss over time, and mood changes. Clinicians sometimes add low-dose hormone replacement (carefully chosen to avoid porphyrogenic formulations) to counteract these effects while still keeping attacks suppressed. It is a balancing act, but for women who are losing a week or more every month to attacks, the benefit often outweighs the cost.
Pregnancy and AIP
Pregnancy itself can trigger AIP attacks, particularly in the first trimester when hormonal shifts are most dramatic.16PubMed. Acute intermittent porphyria in pregnancy: a common misdiagnosis Making matters worse, the abdominal pain, nausea, and vomiting of an AIP attack overlap heavily with common pregnancy complaints, which means attacks can be misdiagnosed or dismissed.17PubMed Central. Treatment of acute intermittent porphyria during pregnancy and posterior reversible encephalopathy syndrome after delivery: A case report Any pregnant woman known to carry an AIP mutation who develops severe or atypical abdominal pain should have porphyrin precursors checked promptly.
Data on hemin use during pregnancy is limited, but clinical experience so far indicates it can be given safely when needed.18PubMed. Acute intermittent porphyria in pregnancy: a common misdiagnosis Givosiran, however, has not been well studied in pregnancy, and decisions about its use require careful discussion between the patient and their medical team. The safest strategy for women planning pregnancy is usually to optimize management beforehand and ensure their obstetric team is aware of the diagnosis.
Long-Term Complications That Shape Ongoing Care
AIP is not just a disease of occasional crises. The toxic precursors appear to do cumulative damage, and two organs bear the heaviest long-term burden: the kidneys and the liver.
Chronic kidney disease affects over half of patients with symptomatic AIP, with kidney function declining at roughly 1 mL per minute per year beyond what normal aging accounts for.19PubMed. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria High blood pressure is common in this population and contributes to the kidney damage, but AIP itself appears to be an independent factor promoting kidney injury, likely through the direct toxic effects of the accumulated precursors.20PubMed Central. Porphyria and kidney diseases Regular monitoring of kidney function and blood pressure management are standard parts of long-term AIP care.
The liver cancer risk is the other major concern. AIP patients face a markedly elevated risk of hepatocellular carcinoma compared to the general population. A 15-year screening study in northern Sweden found the incidence rate ratio was 64 times higher in AIP gene carriers than in the general population.21PubMed. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden The risk rises sharply after age 50, and current guidelines recommend liver imaging every 6 to 12 months starting at that age.22PubMed Central. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review Annual incidence rates in some Scandinavian populations with founder effects run between roughly 0.16% and 0.35%.23PubMed. Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword These numbers may sound small in absolute terms, but they are high enough to justify ongoing surveillance, especially since early-stage liver cancer is far more treatable than late-stage disease.
Liver Transplantation as a Cure
Because the metabolic defect in AIP is largely confined to the liver, replacing the liver effectively cures the disease. Published reports show that no patient had AIP attacks after liver transplantation, with one exception involving an auxiliary graft (a partial transplant that left some of the original liver in place).24PubMed Central. Liver Transplantation for Acute Intermittent Porphyria Early case reports documented that after transplantation, urinary concentrations of heme precursors returned to normal and quality of life improved dramatically.25The Lancet. Liver transplantation for acute intermittent porphyria
Transplantation is reserved for the most severe cases, people whose attacks are frequent and disabling despite all other treatments. The procedure carries its own serious risks, including lifelong immunosuppression, surgical complications, and organ rejection. It also requires a donor organ, which means waiting lists and timing uncertainties. With givosiran now available, the threshold for considering transplant has likely risen, but it remains the only definitive cure for patients who cannot be adequately controlled by medical management alone.
Emerging Therapies on the Horizon
The success of givosiran has opened the door to other molecular approaches. One of the most promising is mRNA therapy, which works from the opposite direction. Instead of silencing a problematic gene, it delivers messenger RNA that instructs liver cells to produce the enzyme AIP patients lack. In a non-human primate model of AIP, repeated doses of this mRNA restored the deficient enzyme’s levels and activity in the liver and protected the animals against acute attacks and the metabolic and neurological disturbances that accompany them.26PubMed Central. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates
Gene therapy aimed at permanently correcting the underlying mutation is also under investigation. Other research groups are working on small molecules that stabilize the mutant enzyme, preventing it from being degraded too quickly in the liver.27PubMed Central. Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators None of these approaches are available clinically yet, but the pipeline is more active than at any point in the disease’s history. For a condition that had essentially one treatment (hemin) for decades, the pace of change over the past few years has been remarkable.
Getting Diagnosed Quickly Enough for Treatment to Work
One of the most persistent problems in AIP is delayed diagnosis. The symptoms of an acute attack, severe abdominal pain, vomiting, confusion, and rapid heart rate, mimic dozens of more common conditions. Patients are often evaluated for surgical emergencies, psychiatric illness, or other neurological disorders before anyone thinks to check for porphyria. A substantial elevation in urinary porphobilinogen on a simple spot urine test is enough to confirm the diagnosis and justify starting hemin immediately.28PubMed. Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians
The practical challenge is getting clinicians to order the test. Many emergency physicians have never seen a case of AIP and do not think to include it in their differential diagnosis. People who know they carry the mutation should carry medical alert information and, ideally, a letter from their specialist that explains the condition and outlines the recommended treatment steps. This small measure can shave hours off the time to treatment during an attack, and in a disease where nerve damage can accumulate with each crisis, those hours matter.